An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation

Autor: Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina B Schoedel, Saskia M Burm, Aras Toker, Theodora W. Salcedo, Dennis Verzijl, David Eisel, Christian Grunwitz, Lena M Kranz, Mathias Vormehr, David P.E. Satijn, Mustafa Diken, Sebastian Kreiter, Kate Sasser, Tahamtan Ahmadi, Özlem Türeci, Esther C.W. Breij, Maria Jure-Kunkel, Ugur Sahin

Publikováno v: OncoImmunology, Vol 11, Iss 1 (2022)

Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors; however, many patients experience treatment resistance. In preclinical models 4-1BB co-stimulation synergizes with ICI by

Externí odkaz: https://doaj.org/article/c2df5e33bb4545efb02c509f371c1d5a

Systematic study of tissue factor expression in solid tumors

Autor: Johann S. deBono, Jeffrey R. Harris, Saskia M. Burm, Adriaan Vanderstichele, Mischa A. Houtkamp, Saida Aarass, Ruth Riisnaes, Ines Figueiredo, Daniel Nava Rodrigues, Rossitza Christova, Siel Olbrecht, Hans W. M. Niessen, Sigrid R. Ruuls, Danita H. Schuurhuis, Jeroen J. Lammerts van Bueren, Esther C. W. Breij, Ignace Vergote

Publikováno v: Cancer Reports, Vol 6, Iss 2, Pp n/a-n/a (2023)

Abstract Background Elevated tissue factor (TF) expression, although restricted in normal tissue, has been reported in multiple solid cancers, and expression has been associated with poor prognosis. This manuscript compares TF expression across vario

Externí odkaz: https://doaj.org/article/0e98ad51ac3645c9bafd82abf01d3681

Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Autor: Ignacio Melero, Maria Jure-Kunkel, Uğur Şahin, Tahamtan Ahmadi, Ulf Forssmann, Özlem Türeci, Kate Sasser, Eleni Lagkadinou, Gaurav Bajaj, Esther C.W. Breij, Sebastian Kreiter, David Satijn, Mustafa Diken, Mark Fereshteh, Edward N. van den Brink, Aras Toker, Theo S. Plantinga, Juliane Quinkhardt, Angelica Sette, Fulvia Vascotto, Dennis Verzijl, Eliana Stanganello, Saskia M. Burm, Theodora W. Salcedo, Bianca Sänger, Jordan M. Blum, Kristina B. Schoedel, Maria E. Rodriguez-Ruiz, Guzman Alonso, Patricia M. LoRusso, Emiliano Calvo, Corinne Maurice-Dror, Eytan Ben-Ami, Ravit Geva, Friederike Gieseke, Isil Altintas, Elena Garralda, Alexander Muik

Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e568b16421048c1e79b8dfceca7e687
https://doi.org/10.1158/2159-8290.22541198.v1

Systematic study of tissue factor expression in solid tumors

Autor: Johann S. de Bono, Jeffrey R. Harris, Saskia M. Burm, Adriaan Vanderstichele, Mischa A. Houtkamp, Saida Aarass, Ruth Riisnaes, Ines Figueiredo, Daniel Nava Rodrigues, Rossitza Christova, Siel Olbrecht, Hans W. M. Niessen, Sigrid R. Ruuls, Danita H. Schuurhuis, Jeroen J. Lammerts van Bueren, Esther C. W. Breij, Ignace Vergote

Publikováno v: de Bono, J S, Harris, J R, Burm, S M, Vanderstichele, A, Houtkamp, M A, Aarass, S, Riisnaes, R, Figueiredo, I, Nava Rodrigues, D, Christova, R, Olbrecht, S, Niessen, H W M, Ruuls, S R, Schuurhuis, D H, Lammerts van Bueren, J J, Breij, E C W & Vergote, I 2022, ' Systematic study of tissue factor expression in solid tumors ', Cancer reports (Hoboken, N.J.) . https://doi.org/10.1002/cnr2.1699
Cancer reports (Hoboken, N.J.). Wiley-Blackwell Publishing Ltd

BACKGROUND: Elevated tissue factor (TF) expression, although restricted in normal tissue, has been reported in multiple solid cancers, and expression has been associated with poor prognosis. This manuscript compares TF expression across various solid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7963355661e32638ebfa646c3038ae79
https://doi.org/10.1002/cnr2.1699

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Autor: Alexander Muik, Elena Garralda, Isil Altintas, Friederike Gieseke, Ravit Geva, Eytan Ben-Ami, Corinne Maurice-Dror, Emiliano Calvo, Patricia M. LoRusso, Guzman Alonso, Maria E. Rodriguez-Ruiz, Kristina B. Schoedel, Jordan M. Blum, Bianca Sänger, Theodora W. Salcedo, Saskia M. Burm, Eliana Stanganello, Dennis Verzijl, Fulvia Vascotto, Angelica Sette, Juliane Quinkhardt, Theo S. Plantinga, Aras Toker, Edward N. van den Brink, Mark Fereshteh, Mustafa Diken, David Satijn, Sebastian Kreiter, Esther C.W. Breij, Gaurav Bajaj, Eleni Lagkadinou, Kate Sasser, Özlem Türeci, Ulf Forssmann, Tahamtan Ahmadi, Uğur Şahin, Maria Jure-Kunkel, Ignacio Melero

Publikováno v: Scientia

Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f076437eb0766ba05d68e27c29cadd1
https://pubmed.ncbi.nlm.nih.gov/35491648